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Abstract
 
We studied complement 1 inhibitor (C1-INH) as an inhibitor of the alternative complement
pathway. C1-INH prevented lysis, induced by the alternative complement pathway, of parox-
ysmal nocturnal hemoglobinuria (PNH) erythrocytes in human serum. It inhibited the binding
of both factors B and C3 to PNH and rabbit erythrocytes and blocked the ability of factor B to
restore alternative-pathway function in factor B–depleted serum. C1-INH did not bind to fac-
tors B or D but did bind to immobilized C3b and cobra venom factor (CVF), a C3b analogue.
C1-INH prevented factor B from binding to CVF-coated beads and dissociated bound factor B
from such beads. Factor B and C1-INH showed cross competition in binding to CVF-coated
beads. Factor D cleaved factor B into Bb and Ba in the presence of C3b. Cleavage was mark-
edly inhibited when C3b was preincubated with C1-INH. C1-INH inhibited the formation of
CVFBb and decreased the C3 cleavage. Removal of C1-INH from serum, in the presence of
Mg-EGTA with an anti–C1-INH immunoabsorbant, markedly increased alternative-pathway
lysis. C1-INH interacts with C3b to inhibit binding of factor B to C3b. At physiologic con-
centrations, it is a downregulator of the alternative pathway convertase.
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Introduction
 
Complement 1 inhibitor (C1-INH)
 
*
 
 is a critically impor-
tant protein that controls activation of multiple plasma me-
diator pathways (1). This protein, a member of the serine
protease inhibitor (serpin) group, originally was described
 
as an inhibitor of C1 (2). It binds stoichiometrically to
the active sites on both C1r and C1s to form a complex
C1-INH-C1r-C1s-C1-INH and thus inhibits activated
C1 (3). In addition, C1-INH has been reported to re-
move the intact C1qrs complex from an activating sur-
face (4) and to inhibit autoactivation of C1 (5). C1-INH is
a known inhibitor of kinin generating (kallikrein), fibri-
nolytic (plasmin), and contact activation (intrinsic) pathway
of the coagulation cascade (factor XIIa, XIIf, and factor
XIa) (1, 6–9). Recently, it has been shown to be an inhibi-
tor of the mannan-binding lectin pathway of complement
activation, inhibiting mannan-binding lectin-associated serine
proteases (MASPs) in that pathway (10).
Because the alternative complement pathway has many
features in common with the classical complement path-
way, and because many proteins of that pathway function
in a manner analogous to proteins of the classical pathway,
we studied the role of the C1-INH in inhibition of the al-
ternative complement pathway. In the alternative comple-
ment pathway, C3b serves a function analogous to that of
C4b; factor B serves a function analogous to C2 and is a
very similar protein; and factor D serves a function analo-
gous to that of C1 of the classical pathway. We began these
experiments with the hypothesis that C1-INH regulates
factor D activity.
 
Materials and Methods
 
Buffers and Reagents.
 
We prepared Veronal-buffered saline
(VBS), pH 7.4; VBS containing 0.1% (wt/vol) gelatin (GVBS);
GVBS containing 0.15 mM CaCl
 
2
 
 and 1 mM MgCl
 
2
 
(GVBS
 
  
 
); GVBS containing 5 mM MgCl
 
2
 
 and 8 mM EGTA
(Mg-EGTA buffer); and GVBS containing 10 mM EDTA
(EDTA buffer) as described (11). All chemicals were purchased
from Sigma-Aldrich, and 
 
125
 
I was obtained from Amersham Phar-
macia Biotech. The Mg-EGTA buffer was at pH 7.4 unless oth-
erwise indicated, when the pH was reduced with HCl to pH 6.5.
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Abbreviations used in this paper: 
 
C1-INH, complement 1 inhibitor; CVF,
 
cobra venom factor; E
 
pnh
 
, PNH erythrocytes; E
 
rb
 
, rabbit erythrocytes;
GVBS, gelatin Veronal-buffered saline; MASP, mannan-binding lectin as-
sociated serine protease; PNH, paroxysmal nocturnal hemoglobinuria. 
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Complement Components and Antibodies.
 
Human factor B, fac-
tor D, C3, cobra venom factor (CVF), and C1-INH and factor
B-depleted, C3-depleted, and C8-depleted human sera were pur-
chased from Advanced Research Technologies, Inc. The IgG
fractions of polyclonal anti-factor B, antifactor D, antifactor H,
anti–C1-INH, anti–human albumin, and anti-C3 were obtained
from Binding Site, Inc.
 
Preparation of Cells and Sera.
 
Peripheral blood from normal
human donors, patients with paroxysmal nocturnal hemoglobin-
uria (PNH), and rabbits was collected into tubes containing
EDTA. The erythrocytes (normal donors, E
 
hu
 
; PNH donors,
E
 
pnh
 
; and rabbits, E
 
rb
 
) were washed with EDTA buffer and
then stored at 4
 
 
 
C in GVBS
 
  
 
. To obtain serum, blood was al-
lowed to clot at room temperature for 30 min, chilled, and then
centrifuged. The patients with PNH all were followed in the he-
matology-oncology clinic at Duke University Medical Center.
In each case, the diagnosis was confirmed by flow cytometry.
Analysis of blood cells showed the absence of the phosphatidyl-
inositol-linked membrane protein CD59. For most of the stud-
ies, the erythrocytes were from a patient who had 
 
 
 
90% type III
PNH erythrocytes, which lyse extensively in acidified serum
(12). Fresh serum was obtained from the same donor, who was
Coombs-negative, to exclude the presence of autoantibodies. For
studies of protein binding or lysis of rabbit erythrocytes, human
serum was absorbed extensively with washed rabbit red cells at
0
 
 
 
C before use.
 
Purification of C1-INH.
 
The C1-INH was further purified
from C1-INH prepared by Immuno-AG (Baxter) using a modifi-
cation of the method of Pilatte et al. (13). Briefly, commercial
C1-INH in 175 mM, pH 7.4 Tris buffer was applied to a 50-ml
jacalin-agarose column and eluted with the same buffer contain-
ing 125 mM Melibiose. The pooled and concentrated C1-INH
fraction was dialyzed and then mixed with Sepharose beads cou-
pled with anti-factor B to remove trace amounts of factor B. The
absorbed C1-INH was applied to a fast protein liquid chromatog-
raphy (FPLC) Superose 12-gel filtration column in VBS to re-
move trace amounts of IgA and anti-factor B IgG. It was further
purified by a FPLC Mono Q column in 20 mM Tris, pH 7.3, and
eluted with the same buffer containing 1 M NaCl. The final C1-
INH preparation contained a major band at 105 kD with a trace
band of degraded C1-INH at 96 kD. It was free of factors H, D,
and B by Western blot analysis.
 
Hemolytic Assays.
 
The erythrocytes (10
 
7
 
 E
 
pnh
 
 or E
 
rb
 
) were
incubated with 1:5 diluted human serum in Mg-EGTA-GVBS in
a final volume of 200 
 
 
 
l at 37
 
 
 
C for 30 min. To stop the reaction,
1 ml of EDTA buffer was added. After centrifugation, the super-
natant optical density was measured at 412 nm. Before adding the
cells, C1-INH or control protein was added to diluted serum to
study the inhibitory activity of C1-INH.
 
Factor B Hemolytic Activity.
 
Rabbit red cells (1.5 
 
 
 
 10
 
8
 
, 100
 
 
 
l in Mg-EGTA buffer, pH 6.5) were incubated with 100 
 
 
 
l of a
1:10 dilution of factor B-depleted human serum in the same
buffer, with 5 
 
 
 
l of factor B (0.25 
 
 
 
g) added. To this mixture, 10
 
 
 
l of buffer containing human serum albumin (HSA) or C1-INH
was added. The mixture was then incubated at 37
 
 
 
C for 30 min.
To stop the reaction, 1 ml of EDTA buffer was added. After cen-
trifugation, the optical density of the supernatant was measured at
412 nm.
 
Isotope Labeling.
 
Factor B (1.4 
 
 
 
Ci/
 
 
 
g), factor D (0.04 
 
 
 
Ci/
 
 
 
g), C3 (1.43 
 
 
 
Ci/
 
 
 
g), C1-INH (0.32 
 
 
 
Ci/
 
 
 
g), and anti-B
(0.113 
 
 
 
Ci/
 
 
 
g), anti-D (0.06 
 
 
 
Ci/
 
 
 
g), and anti-C3 (0.19 
 
 
 
Ci/
 
 
 
g) were radiolabeled with 
 
125
 
I using Iodobeads according to the
manufacturer’s instructions (Pierce Chemical Co.). Free iodine
 
was removed by small-scale gel filtration on a Bio-Spin column
(Bio-Rad Laboratories). The labeled factor B and C3 were func-
tional in a hemolytic assay.
 
Dot-Blot Analysis.
 
C3b, Factor D, Factor B, or BSA, all at 50
 
 
 
g/ml in 200 
 
 
 
l of PBS was dotted onto nitrocellulose paper us-
ing Bio-Dot apparatus (Bio-Rad Laboratories). The paper with
dotted proteins was blocked with 3% nonfat drymilk for 1 h at
room temperature, washed, and incubated with 
 
125
 
I–C1-INH
(2.5 
 
 
 
g/ml) for 1 h at room temperature. Radioactivity was de-
termined after washing four times in PBS-Tween.
 
Coupling of Proteins to Cyanogen Bromide–activated Sepharose 4B.
 
The CVF, anti-C1-INH, and anti-HSA were coupled to
CNBr-activated Sepharose 4B beads according to the manufac-
turer’s instructions (Sigma-Aldrich). Briefly, CNBr-activated
Sepharose 4B powder was allowed to swell in cold 1 mM HCl
(200 ml/g dry powder). The beads were washed five times with
0.1 M NaHCO
 
3
 
, 0.5 M NaCl, pH 8.4 (coupling buffer), and im-
mediately the various proteins in coupling buffer were added.
Beads with added proteins at 1 mg/ml/gram dry power were in-
cubated overnight at 4
 
 
 
C, using an end-over-end mixer. The
beads were spun down, and unbound protein was washed away
with coupling buffer. Unbound sites were blocked with 0.2 M
glycine, pH 8.0 overnight at 4
 
 
 
C, and the beads were then
washed multiple times to remove the blocking solution. The first
wash solution contained coupling buffer; the second acetate
buffer (0.1 M, pH 4.0, 0.5 M NaCl). This wash cycle was re-
peated three times. After washing in VBS the beads were stored at
4
 
 
 
C with 0.05% azide. The protein concentration in the coupling
buffer was measured at 280 nm before and after coupling; the
coupling efficiency was higher than 90%.
 
Effect of C1-INH on Binding of Serum Factor B and C3 to Erythro-
cytes.
 
The erythrocytes (5 
 
  
 
10
 
7
 
 E
 
hu
 
, E
 
pnh
 
, or E
 
rb
 
) were in-
cubated with C8-depleted serum (1:10 diluted in Mg-EGTA
buffer) at pH 6.5 or 7.4 at 37
 
 
 
C for 30 min. After washing twice
with cold Mg-EGTA buffer, 
 
125
 
I-labeled antibodies were added
as indicated. The mixture was incubated at 4
 
 
 
C for 1 h. After
washing twice with Mg-EGTA buffer, the radioactivity of the
cell pellet was determined. Bovine serum albumin or human se-
rum albumin was used as the control protein.
 
Effect of C1-INH on Binding of Factor B to CVF Sepharose
Beads.
 
Sepharose beads with bound CVF, 50 
 
 
 
l containing
 
 
 
50% beads in pH 6.5 Mg-EGTA buffer, were incubated with
 
125
 
I-labeled factor B (5–25 ng), with or without C1-INH or con-
trol protein (300 
 
 
 
g/ml) added at 37
 
 
 
C for 15 min. After wash-
ing twice with 2 ml of cold Mg-EGTA buffer, the bound factor
B was measured in a gamma scintillation counter. In factor B dis-
sociation studies, CVF beads with bound factor B were further
incubated with C1-INH or control protein (300 
 
 
 
g/ml) at 37
 
 
 
C
for 15 min. We added 1 ml of cold Mg-EGTA buffer and, after
centrifugation, measured the pellet and supernatant radioactivity.
 
Factor B Cleavage.
 
Factor B was cleaved by incubating 250 ng
(5 
 
 
 
l) 
 
125
 
I-labeled factor B, 5–100 ng of C3b (1 
 
 
 
l) and 0.1–100
ng of factor D (1 
 
 
 
l) at 37
 
 
 
C for 60 min. The reaction was
stopped by adding 10 
 
 
 
l of twice-concentrated SDS-PAGE sam-
ple buffer. In some experiments, a limiting amount of C3b (10
ng) or factor D (0.5 ng) was preincubated with C1-INH (2 
 
 
 
g)
or control HSA (2 
 
 
 
g) at 37
 
 
 
C for 10 min before adding other
components. We loaded 10 
 
 
 
l into wells of a 7.5% SDS-PAGE
in a mini electrophoresis system (Bio-Rad Laboratories).
 
C3 Cleavage.
 
CVF Sepharose beads 20 
 
 
 
l in GVBS were in-
cubated with factor B (1 
 
 
 
g) and D (0.1 
 
 
 
g) at 37
 
 
 
C for 10 min
to generate Sepharose CVFBb. After washing in GVBS
 
  
 
 to
remove free B and D, the solid phase CVFBb beads were incu- 
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bated with 
 
125
 
I-labeled human C3 (250 ng) at 37
 
 
 
C for 60 min.
To stop the reaction, 20 
 
 
 
l of twice-concentrated SDS-PAGE
sample buffer was then added. In the C1-INH inhibition experi-
ments, CVF beads were preincubated with C1-INH (2 
 
 
 
g) or
control HSA (2 
 
 
 
g) at 37
 
 
 
C for 10 min before adding factor B
and D. After washing, 
 
125
 
I-C3 was added and the procedure
above was followed.
 
Electrophoresis and Autoradiography.
 
PAGE was performed ac-
cording to the procedure of Laemmli (14) using 7.5% ready gel
(Bio-Rad Laboratories). The 
 
125
 
I-labeled protein was loaded into
wells (10 
 
 
 
l/well). After electrophoresis, the gel was dried, and
Eastman Kodak XRP X-ray film was exposed to the dried slab
gel wrapped in cellophane for 24 h at 
 
 
 
20
 
 
 
C before developing.
 
Data Presentation.
 
Data represent the mean 
 
 
 
 SEM of single
experiments and is representative of at least three experiments all
of which gave similar results. Means were compared using a two-
 
tailed 
 
t
 
 test and in each case the difference was significant at the
0.01 level or below.
 
Results
 
C1-INH Inhibits PNH Cell Lysis by the Alternative Com-
plement Pathway.
 
The PNH erythrocytes were incubated
with acidified (pH 6.5) normal human serum in Mg-EGTA
buffer (Fig. 1) or the patient’s own acidified serum (data
not shown) with purified C1-INH or control protein
added. Highly purified C1-INH, but not control protein,
prevented lysis of PNH erythrocytes in Mg-EGTA buffer
in a dose-dependent manner. In experiments not shown,
C1-INH similarly inhibited lysis of rabbit erythrocytes in
Mg-EGTA buffer by the alternative pathway.
 
C1-INH Inhibits Factor B and C3 Binding to Rabbit and
PNH Erythrocytes.
 
The E
 
rb
 
 or E
 
pnh
 
 were incubated with
diluted (1:10) C8-depleted serum brought to pH 6.5 in
Mg-EGTA buffer with or without added purified C1-INH
or control protein (BSA). After incubation and washing, la-
beled anti-factor B or anti-C3 was added to detect factor B
or C3 binding. The C1-INH inhibited factor B and C3
binding to rabbit erythrocytes in a dose-dependent manner
(Fig. 2). Control protein (BSA) had no effect. Similarly,
C1-INH inhibited factor B and C3 binding to PNH eryth-
rocytes (data not shown).
 
C1-INH Does Not Interact with Factor B or Factor D, but
Does Interact with C3b.  Direct binding of C1-INH to
various complement proteins was studied using 125I-labeled
factor B or factor D. Labeled factor B or D was incubated
with C1-INH at room temperature for 1 h and anti–C1-
INH was added and incubated for 30 min. Saturated am-
monium sulfate was added at 4 C for 1 h to precipitate
complexes. After washing twice with 50% saturated ammo-
nium sulfate, we measured the radioactivity of the pellet. In
a second type of experiment, labeled C1-INH was added
to a 96-well microtiter plate, to which was bound factor B,
factor D, or BSA control. After incubation and washing,
radioactivity in the well was determined. In a third type of
Figure 1. C1-INH inhibits PNH cell lysis in acidified serum. Epnh in
pH 6.5 Mg-EGTA buffer (50  l) was incubated with 100  l diluted (1:5)
acidified normal human serum. To this mixture, 50  l of HSA ( ) or
C1-INH ( ) was added. The mixture was then incubated at 37 C for 30
min. To stop the reaction, 1 ml of EDTA buffer was added. After centrif-
ugation, the optical density of the supernatant was measured at 412 nm
and percent lysis was calculated.
Figure 2. C1-INH inhibits factor B
and C3 binding to rabbit erythrocytes.
The Erb was incubated with C8-
depleted serum (1:10 diluted in Mg-
EGTA buffer) at pH 6.5 with added
C1-INH or BSA ( ) for 30 min at
37 C. After washing, 125I-labeled anti-
bodies were added to detect factor B (A:
 ) or C3 (B:  ) binding.1612 C1 Esterase Inhibitor Regulates the Alternative Complement Pathway
experiment, a PAGE migration-retardation method was
used. Labeled factor B or factor D was incubated with C1-
INH or BSA. After electrophoresis, the proteins were
transferred to nitrocellulose membrane and exposed to
films for 24 h before developing. The protein-migration
pattern with or without addition of C1-INH was com-
pared. All the above attempts failed to detect interaction
between labeled proteins and C1-INH or control proteins.
However, C1-INH interacted with immobilized C3b in
the dot-blot analysis (Fig. 3), but not with Factor B, Factor
D, and BSA.
C1-INH Blocks the Ability of Factor B to Restore the
Hemolytic Activity of Factor B–depleted Serum. Factor B–
depleted serum (1:10 diluted) in Mg-EGTA buffer had no
ability to lyse rabbit red cells in alternative-pathway assays.
Its activity was restored when purified human factor B (5
 g) was added. Addition of C1-INH prevented factor B
from restoring the activity of factor B-depleted serum in a
dose-dependent manner (Fig. 4). Control HSA had no ef-
fect. The C1-INH purchased from Advanced Research
Technologies as well as C1-INH prepared by a rigorous
purification procedure (see Materials and Methods) showed
similar activity.
Binding of Factor B and C1-INH to CVF-coated Sepharose
Beads and Binding Inhibition by C1-INH or Factor B. Fac-
tor B or C1-INH bound to CVF beads in Mg-EGTA
buffer in a dose-dependent manner (Fig. 5). The control
protein (HSA) showed little binding. When CVF-coated
Sepharose beads were preincubated with C1-INH or factor
B, the binding of labeled factor B was inhibited by C1-
Figure 3. C1-INH binds to immobilized C3b. C3b, Factor B, Factor
D, BSA, or buffer control on nitrocellulose paper was incubated with
125I-labeled C1-INH for 1 h at room temperature. After washing, radio-
activity was determined. Nonspecific binding from the buffer control was
subtracted from C3b, factor B, factor D or BSA binding. *P   0.01 versus
BSA control.
Figure 4. C1-INH blocks factor B hemolytic activity. The Erb in pH
6.5 Mg-EGTA buffer was incubated with factor B-depleted human serum.
To this mixture, 15  l of factor B and HSA ( ), factor B, and purified
C1-INH from two sources (prepared as in Materials and Methods, solid
circles and from Advanced Research Technologies;  ) was added. The
mixture was then incubated at 37 C for 30 min. To stop the reaction, 1 ml
of EDTA buffer was added. After centrifugation, the optical density of the
supernatant was measured at 412 nm, and percent lysis was calculated.
Figure 5. Factor B and C1-INH binding to CVF beads. CVF-Sepharose
beads were incubated with: (A) 125I-labeled factor B ( ) or control protein
HSA ( ); (B) 125I-labeled C1-INH ( ) or control protein HSA ( ) at
37 C for 15 min. After washing twice with 2 ml of cold Mg-EGTA buffer,
the bound proteins were measured in a gamma scintillation counter.1613 Jiang et al.
INH and C1-INH binding was inhibited by factor B in a
dose-dependent manner (Fig. 6). The control protein
(HSA) had no inhibition activity.
Dissociation of Factor B from CVF-coated Beads Complex by
C1-INH. When complex of CVF-bound beads with
bound  125I-factor B was incubated with C1-INH for 15
min at 37 C, a portion of the radioactivity in the pellet was
released into the supernatant (30% compared with 8% for
control; Fig. 7), indicating that C1-INH dissociated bound
factor B from the CVF beads.
C1-INH Inhibits Factor B and C3 Cleavage. Factor B
bound to C3b, and, once bound, was cleaved by factor D
into Bb and Ba. When C3b was incubated with C1-INH
before adding 125I-labeled factor B and factor D, factor B
cleavage was inhibited. Less Bb and Ba were formed, as
shown in Fig. 8. The control HSA had no effect. To deter-
mine whether reduced B cleavage, in turn, results in less
C3 cleavage, the solid phase CVFBb (C3 convertase) was
generated by incubation of CVF Sepharose beads, factor B,
and factor D in the presence or absence of C1-INH and
then washed to remove fluid-phase Bb and unbound pro-
teins. In the absence of C1-INH, the formed CVFBb was
able to cleave C3 to form C3b (C3   chain into   chain)
(Fig. 9, lane 2). When C1-INH was present during genera-
tion of CVFBb, the 125I-C3   chain remained intact (Fig.
9, lane 4), indicating that less CVFBb was formed. The
control HSA had no effect (Fig. 9, lane 3). We also mea-
sured the activity of solid-phase CVFBb in consuming
hemolytic C3. The C1-INH inhibited the generation of
CVFBb, and thus more hemolytic C3 activity remained in
the supernatant (data not shown).
Absorption of C1-INH from Normal Serum. It is impor-
tant to know whether levels of C1-INH in normal plasma
regulate alternative-pathway activity. To examine this
question, serum in Mg-EGTA buffer (to prevent activation
Figure 6. Inhibition of factor B or C1-INH binding by
C1-INH or factor B. The CVF-Sepharose beads were in-
cubated with unlabeled C1-INH ( ) or HSA ( ) before
adding 125I-labeled factor B. Inhibition of binding of factor
B by C1-INH but not control protein is shown (A). Then,
CVF Sepharose beads were incubated with unlabeled fac-
tor B ( ) or HSA ( ), to which 125I-labeled C1-INH was
added. After washing twice with two ml cold Mg-EGTA
buffer, the bound proteins were measured in a gamma
counter. Inhibition of binding of C1-INH by factor B is
shown (B).
Figure 7. C1-INH dissociates bound factor B from CVF. The CVF
beads with bound factor B were washed and incubated with C1-INH or
control protein HSA at 37 C for 15 min. We added 1 ml of cold Mg-
EGTA buffer, and, after centrifugation, measured the supernatant radio-
activity. *P   0.001 versus HSA control.1614 C1 Esterase Inhibitor Regulates the Alternative Complement Pathway
of the classical pathway) was exposed in the cold to an anti–
C1-INH or anti-HSA immunoabsorbant. The anti–C1-
INH column, removed  80% of the C1-INH activity but
not the anti-HSA column (Fig. 10). Lytic activity of the
absorbed serum by the alternative pathway increased
whereas that of the control was unchanged, suggesting that
physiologic concentrations of C1-INH in normal serum
downregulate activity of the alternative pathway.
Discussion
C1-INH is a heavily glycosylated, single chain, plasma
glycoprotein with an apparent molecular weight of 105 kd
on sodium dodecyl sulfate-PAGE. It consists of 478 amino
acids comprising a backbone molecular weight of 52,880
(1). The protein acts as a serine protease inhibitor (serpin)
binding to and forming covalent bonds with a variety of
plasma proteases and thus inhibiting their activity (2, 3).
The protein is known to inhibit C1s and C1r, two sub-
components of the complement protein C1. It is for these
properties that it received its name. However, it is a known
inhibitor of factor FXIIa and FXIIf, kallikrein, FXIa, plas-
min, MASP1, and MASP2. Thus it inhibits proteins of the
intrinsic coagulation, kinin generating, and fibrinolytic
pathways, as well as the mannan binding lectin pathway of
complement activation (5–9). As such, it is a potent down
regulator of inflammation. C1-INH has been administered
to animals in a variety of animal models of disease and
shown to have profound inhibitory activities in situations
ranging from ischemia-reperfusion injury as occurs in myo-
cardial infarct to transplant rejection (15–17).
Here we report that C1-INH is also active in downregu-
lating function of the alternative complement pathway.
C1-INH downregulates lysis of complement sensitive
erythrocytes from patients with paroxysmal nocturnal he-
moglobinuria in acidified, Mg-EGTA serum, lysis known
to be caused by activation of the alternative pathway. It also
is a potent inhibitor of lysis in a second, widely used, assay
Figure 8. C1-INH inhibits factor B cleavage. A limiting amount of
C3b (10 ng) was preincubated with C1-INH (2  g) or control HSA (2
 g) at 37 C for 10 min before adding factor D (10 ng) and 125I-labeled
factor B (250 ng). The mixture was incubated at 37 C for 60 min and
stopped by adding 10  l of twice concentrated SDS-PAGE sample buffer.
10  l was loaded into wells of a 7.5% SDS-PAGE. Autoradiography indi-
cates that C1-INH inhibits factor B cleavage.
Figure 9. C1-INH inhibits C3 convertase. CVF beads were preincu-
bated with C1-INH (2  g) or control HSA (2  g) at 37 C for 10 min be-
fore adding factors B (1  g) and D (0.1  g). The mixture was incubated
at 37 C for 10 min to generate Sepharose CVFBb. After washing in
GVBS   to remove free factors B and D, the solid-phase CVFBb beads
were incubated with 125I-labeled human C3 (250 ng) at 37 C for 60 min.
To stop the reaction, 20  l of twice-concentrated SDS-PAGE sample
buffer was added. Autoradiography after SDS-PAGE indicated that
C1-INH inhibits C3 cleavage.
Figure 10. C1-INH and alternative-complement activities in C1-INH
depleted serum. C1-INH functional activity (white bars) and alternative-
complement pathway activity (black bars) in normal human serum, serum
after passage over Sepharose-bound anti-HSA columns, and serum after
passage over anti-C1-INH columns at 0 C. *P   0.001 versus NHS or
anti-HSA control.1615 Jiang et al.
for alternative pathway function, the lysis of rabbit erythro-
cytes in Mg-EGTA serum. In both of these cases, we find
that acidification of serum contributes to increased binding
of factor B and C3 to the erythrocytes when examined di-
rectly and this increase in binding is inhibited by C1-INH.
We have explored the basis of this unexpected observa-
tion. Our initial hypothesis was that C1-INH would bind
and inhibit factor D, the C1 like enzyme of the alternative
pathway. If such were the case, it might be expected to in-
hibit the protease by forming a covalent bond, as with all of
the aforementioned proteases. Initial experiments demon-
strated binding of C1-INH to C3b, but not factor B or D.
In a variety of experimental models we also found that it
binds to CVF, a C3b analogue found in the venom of co-
bras. Further studies demonstrated that C1-INH blocked
the ability of factor B to restore the hemolytic activity of
factor B-depleted serum. In binding to CVF it appears to
interact with a site close to or identical with the factor B
binding site on CVF. There is dose-dependent cross-inhi-
bition of C1-INH and factor B binding. Moreover factor B
is known to form a firm complex with CVF-coated beads
and it is of interest that C1-INH can partially displace fac-
tor B from the complex.
It is known that when CVF coated beads are mixed with
purified factor B and factor D, C3 cleavage, via the alterna-
tive pathway, is initiated. We find that C1-INH on inter-
acting with CVF prevents such C3 cleavage.
To asses the point further, purified C3b was incubated
with purified factor B and factor D in the presence or
absence of C1-INH. In this reaction, factor B binds to
C3b and in the presence of factor D, factor B is cleaved
into Ba and Bb. This cleavage leads to the activation of
the alternative pathway convertase and formation of a
C3-cleaving enzyme. In the presence of C1-INH, but
not in the presence of control protein, B cleavage was
inhibited and the generation of Ba and Bb was markedly
reduced.
These experiments suggest that one function of C1-INH
is to regulate activation of the alternative pathway, presum-
ably by binding to C3b and inhibiting the formation of or
destabilizing the complex with factor B. We have no evi-
dence thus far that the function of C1-INH in these studies
is to act as a serpin. It does not appear to inhibit enzymatic
activity, as it has in other functional studies.
In these studies, C1-INH is in marked molar excess and
it was important to assess whether C1-INH has a regula-
tory function in normal serum. To normal serum was
added Mg-EGTA to prevent activation of the classic path-
way. C1-INH was removed by an immunoabsorption
method. Activity of the alternative pathway increased
markedly, suggesting that even at physiological concentra-
tions C1-INH acts to control activation of the alternative
pathway.
It is of interest that this is not the first observation of in-
hibition of protein function by C1-INH without formation
of a covalent bond. It is known that C1-INH downregu-
lates activation of C1 in normal plasma via a noncovalent
interaction (5).
The plasma concentration of C1-INH is 200–300  g/
ml. It is an acute-phase protein and rises strikingly during
inflammatory states. In alternative pathway activation small
amounts of C3 with a cleaved thioester bond are generated
spontaneously. If they bind to a surface on which the C3 is
protected from inactivation by factors H and I, a C3 con-
vertase is formed after the binding of factors B and D and
marked alternative pathway amplification occurs. It is likely
that C1-INH acts at these early steps in alternative pathway
activation when limited amounts of C3 are activated and
can be inhibited by C1-INH.
Interestingly, individuals who are heterozygous for a
C1-INH gene defect and who functionally have one
third to one half normal C1-INH function have HAE as-
sociated with attacks of mediator activation and tissue
swelling. This disease can be life threatening. Current ev-
idence suggests that these attacks are caused by the in-
ability of heterozygous levels of C1-INH protein to
regulate the generation of bradykinin by the kinin gener-
ating pathway (18). Patients with HAE have low levels of
C4, reflecting uncontrolled activation of C1. The level
of high-molecular-weight kininogen however, is normal
between attacks, but falls during attacks, suggesting that
C1-INH is not needed for regulation of the kinin-gener-
ating pathway between attacks of edema (18–20). Our
data suggest that C1-INH also regulates the alternative
pathway under physiologic conditions. Presumably, be-
cause there are many other regulators of C3 in plasma,
including factors H and I, DAF (CD55), CR1 (CD35),
and MCP (CD46), the C3 level does not fall during at-
tacks of HAE. Nevertheless, C3 turnover has been
shown to be increased and C3 degradation products do
rise during these attacks (20).
In conclusion, these data present evidence that C1-
INH, thought to inhibit classical pathway and mannan-
binding lectin binding pathway, also functions as a reg-
ulatory protein of the third pathway of complement
activation, the alternative pathway. At sites of inflamma-
tion, local concentration of C1-INH may be very impor-
tant in controlling alternative pathway activity. There are
many papers that suggest that C1-INH infusions can con-
trol a wide variety of inflammatory process (17). At
present, therapeutic preparations of C1-INH are used to
raise C1-INH protein levels, at times to above physio-
logic values. The ability of C1-INH to control all path-
ways of complement activation may be therapeutically
important in the future.
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